#### FORM 4 Check this box if no

longer subject to

may continue. See

Instruction 1(b).

Section 16. Form 4 or Form 5 obligations

# Washington, D.C. 20549

	OMB APPROVAL						
	OMB Number:	3235-0287					
	Estimated average	burden					
3	hours per response	e 0.5					

0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the

Investment Company Act of 1940

(France or T)	pe reesponse	)														
1. Name and Address of Reporting Person *- Hoffman Freddie Ann			2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RXHN.OB]						_x_	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director Officer (give title below) Other (specify below)						
	7	(First) ARMACEUTICA R DRIVE		3. Date o 06/01/20			nsact	tion (Month/	Day/Year)							
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Fe	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person					
ROCKVI (Cit	LLE, MD	(State)	(7:-)								Form filed by More than One Reporting Person					
(Cit	у)	(State)	(Zip)			Tab	le I ·	- Non-Deriv	tive Securitie	Securities Acquired, Disposed of, or Beneficially Owned						
1.Title of S (Instr. 3)				Execution Date, if Code		8) (A	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  (A) or Amount (D) Price		D) Owne Trans (Instr	Owned Following Reported Transaction(s) (Instr. 3 and 4)			wnership of orm:	Nature Indirect eneficial wnership nstr. 4)		
- · ·			1 1 0 11		.,						·				<u>'</u>	
Kemmuer.	Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4.	, ca	5. Numb		6. Date Exe		_	Title and		8. Price of	9. Number of	10.	11. Nature
	Conversion or Exercise Price of Derivative Security	Date	Execution Date, if	Transac Code			ve es d	Expiration I	Expiration Date Amo Month/Day/Year) Under Securior		mount of nderlying ecurities	ount of Der erlying Sec			Ownership Form of Derivative Security: Direct (D) or Indirect	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Ti	itle	Amount or Number of Shares				
Stock Options (right to buy)	\$ 1.40							06/11/200	8 06/11/201	/	ommon Stock	20,000		20,000	D	
Stock Options (right to buy)	\$ 3.24							(1)	06/30/201	X I	ommon Stock	20,000		20,000	D	
Stock Options (right to buy)	\$ 1.28	06/01/2009		A		20,000		<u>(2)</u>	06/01/201	91	ommon Stock	20,000	\$ 0	20,000	D	

## **Reporting Owners**

Donastino Comerci Name / Addisor	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Hoffman Freddie Ann C/O REXAHN PHARMACEUTICALS, INC. 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	X					

#### **Signatures**

/s/ Tae Heum Jeong, as attorney-in-fact for Freddie Ann Hoffman	06/02/2009
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options vest and become exercisable in full on June 30, 2009.
- (2) These options vest and become exercisable in full on June 1, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.